Clínic Barcelona

A IDIBAPS-IIBB-CSIC team proposes a potential biomarker for early diagnosis of Alzheimer's disease

The search for a reliable way to diagnose Alzheimer's disease is one of the great challenges of modern biomedicine. IDIBAPS-IIBB-CSIC Neurobiology Unit, led by Dr. Ramon Trullás, has discovered a potential biomarker that, if confirmed, could change the fundamentals of the disease. According to the study published in Annals of Neurology, with Petar Podlesniy and Joana Figueiro-Silva as its first authors, patients in preclinical stages of the disease may present reduced levels of mitochondrial DNA in the cerebrospinal fluid. The study involved other basic researchers from IDIBAPS-IIBB-CSIC, like Dr. Nuria Serra, and clinical researchers as Dr. Albert Lladó, Dr. Anna Antonell, Dr. Raquel Sánchez-Valle and Dr. Jose Luis Molinuevo from IDIBAPS - Hospital Clínic, with the support of the CIBER on Neurodegenerative Diseases (CIBERNED).